Bristol Meyers Squibb Breakdown

$BMY, an excellent company in which is on my watchlist.

Current Price: $56.75

52/wk High: $68.34

52/wk Low: $42.48

Read below for full breakdown!

Bristol-Meyers Squibb is an excellent stock and I believe investment at its current levels.

The company currently has several drugs out or in the works: Eliquis, Opdivo, Orencia, Yerovoy, and Sprycel.

These drugs focus on a large multitude of health issues including, preventative stroke action, treatment of non-active small cell lung cancer, rheumatoid arthritis treatment, leukemia treatment, and skin cancer treatment.

The company is strong in cardiovascular issues, cancer, and autoimmune disease which are all huge in potential.

Furthermore, $BMY recently penned a deal with Celgene. The deal will hit 40% in acceleration from its first year which is roughly $800 million in returns from 2020 to 2022.

Not only that but $BMY just announced that Opdivo has received FDA approval for treatment of advanced esophageal squamous cell carcinoma.

With great Q1 earnings of $1.72 EPS and a beat in earnings with $10.8 billion in revenue, an 82% increase.

In all $BMY has consistently grown and been a resistant name to economic issues.

Furthermore, the big money loves the stock as well, with big firms like Blackrock Trust, JP Morgan, and many more being top holders of the name, all of which with over $2 billion in holdings of $BMY.

Overall I love the name and its always on my watchlist. If $BMY drops any further I will highly consider opening a position but I am already strongly considering a buy at $57, which in my opinion is too cheap.

While analysts only have a mean price target of $66, I think it could get to $75 at least, if not $80 given the multitude of future catalysts with future drugs.

Overall I like the name, am strongly considering a position, and recommend it.

Disclaimer: This is not investment advice, and I do not currently hold stock in $BMY.